Stocks / NASDAQ / SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc.

Our Opinion

SAB Biotherapeutics Inc. is on the Cruelty-Free Investing usage of animals list because they undertake pre-clinical studies on animals to examine the safety profile of their medications.

Supporting Evidence:

The company stated in the following news article that they use animals for drug testing.

“The data also showed that SAB-185 COVID-19 polyclonal antibody therapeutic candidate was effective in animal models against all tested SARS-CoV2 variants, including some of the recently evolving Omicron variants.” Read the following article

Company Description

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.

Company Website: